2023年10月1日至2024年3月31日，威斯康星州婴儿和孕妇RSV免疫接种情况。

IF 4.5 3区医学 Q2 IMMUNOLOGY

Vaccine Pub Date : 2025-01-04 DOI:10.1016/j.vaccine.2024.126674

Maddie Kemp, Ashley Capriola, Stephanie Schauer

{"title":"2023年10月1日至2024年3月31日，威斯康星州婴儿和孕妇RSV免疫接种情况。","authors":"Maddie Kemp, Ashley Capriola, Stephanie Schauer","doi":"10.1016/j.vaccine.2024.126674","DOIUrl":null,"url":null,"abstract":"<div><div>Respiratory syncytial virus (RSV) is the leading cause of hospitalizations among infants in the United States. New strategies to prevent RSV among infants and high-risk young children include the maternal RSVpreF vaccine (Abrysvo, Pfizer Inc.) and nirsevimab (Beyfortus, Sanofi and AstraZeneca), a long-acting monoclonal antibody. We examined immunization coverage among infants born during the 2023–24 RSV season and pregnant persons utilizing data from the Wisconsin Immunization Registry and Office of Vital Records to evaluate uptake of both products and overall infant protection against RSV. 5056 (18.2 %) infants received nirsevimab and 4767 (17.2 %) persons who gave birth during this timeframe received the maternal RSVpreF vaccine; 0.8 % of parent-infant dyads received both products. Overall, 36.2 % of infants were protected from RSV. These findings suggest that improved efforts on several fronts are needed to ensure equitable and timely access to both RSV products while also increasing the number of infants protected against RSV.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"47 ","pages":"Article 126674"},"PeriodicalIF":4.5000,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"RSV immunization uptake among infants and pregnant persons — Wisconsin, October 1, 2023-March 31, 2024\",\"authors\":\"Maddie Kemp, Ashley Capriola, Stephanie Schauer\",\"doi\":\"10.1016/j.vaccine.2024.126674\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Respiratory syncytial virus (RSV) is the leading cause of hospitalizations among infants in the United States. New strategies to prevent RSV among infants and high-risk young children include the maternal RSVpreF vaccine (Abrysvo, Pfizer Inc.) and nirsevimab (Beyfortus, Sanofi and AstraZeneca), a long-acting monoclonal antibody. We examined immunization coverage among infants born during the 2023–24 RSV season and pregnant persons utilizing data from the Wisconsin Immunization Registry and Office of Vital Records to evaluate uptake of both products and overall infant protection against RSV. 5056 (18.2 %) infants received nirsevimab and 4767 (17.2 %) persons who gave birth during this timeframe received the maternal RSVpreF vaccine; 0.8 % of parent-infant dyads received both products. Overall, 36.2 % of infants were protected from RSV. These findings suggest that improved efforts on several fronts are needed to ensure equitable and timely access to both RSV products while also increasing the number of infants protected against RSV.</div></div>\",\"PeriodicalId\":23491,\"journal\":{\"name\":\"Vaccine\",\"volume\":\"47 \",\"pages\":\"Article 126674\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2025-01-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vaccine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0264410X24013562\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X24013562","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

呼吸道合胞病毒（RSV）是美国婴儿住院的主要原因。在婴儿和高危幼儿中预防RSV的新策略包括母体rssvpref疫苗（Abrysvo, Pfizer Inc.）和长效单克隆抗体nirsevimab （Beyfortus， Sanofi和AstraZeneca）。我们利用威斯康星州免疫登记和生命记录办公室的数据，检查了2023-24年RSV季节出生的婴儿和孕妇的免疫覆盖率，以评估产品的摄取和婴儿对RSV的总体保护。5056名（18.2%）婴儿接种了nirsevimab， 4767名（17.2%）在此期间分娩的人接种了RSVpreF疫苗；0.8%的父母和婴儿同时使用了这两种产品。总体而言，36.2%的婴儿免受呼吸道合胞病毒感染。这些发现表明，需要在几个方面加强努力，以确保公平和及时获得这两种呼吸道合胞病毒产品，同时增加预防呼吸道合胞病毒的婴儿数量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

RSV immunization uptake among infants and pregnant persons — Wisconsin, October 1, 2023-March 31, 2024

Respiratory syncytial virus (RSV) is the leading cause of hospitalizations among infants in the United States. New strategies to prevent RSV among infants and high-risk young children include the maternal RSVpreF vaccine (Abrysvo, Pfizer Inc.) and nirsevimab (Beyfortus, Sanofi and AstraZeneca), a long-acting monoclonal antibody. We examined immunization coverage among infants born during the 2023–24 RSV season and pregnant persons utilizing data from the Wisconsin Immunization Registry and Office of Vital Records to evaluate uptake of both products and overall infant protection against RSV. 5056 (18.2 %) infants received nirsevimab and 4767 (17.2 %) persons who gave birth during this timeframe received the maternal RSVpreF vaccine; 0.8 % of parent-infant dyads received both products. Overall, 36.2 % of infants were protected from RSV. These findings suggest that improved efforts on several fronts are needed to ensure equitable and timely access to both RSV products while also increasing the number of infants protected against RSV.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Vaccine 医学-免疫学

CiteScore

8.70

自引率

5.50%

发文量

992

审稿时长

131 days

期刊介绍： Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.